Last reviewed · How we verify
Oxcarbazepine XR
Oxcarbazepine XR is an extended-release anticonvulsant that blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizures.
Oxcarbazepine XR is an extended-release anticonvulsant that blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizures. Used for Partial-onset seizures (monotherapy and adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy).
At a glance
| Generic name | Oxcarbazepine XR |
|---|---|
| Also known as | SPN-804O, Oxtellar XR |
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Drug class | Anticonvulsant; voltage-gated sodium channel blocker |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Oxcarbazepine is a prodrug that is metabolized to its active metabolite, which selectively blocks voltage-gated sodium channels in their inactive state, stabilizing neuronal membranes and reducing repetitive firing. This mechanism reduces the propagation of seizure activity across neural networks. The extended-release formulation provides sustained drug levels with once-daily dosing.
Approved indications
- Partial-onset seizures (monotherapy and adjunctive therapy)
- Generalized tonic-clonic seizures (adjunctive therapy)
Common side effects
- Dizziness
- Somnolence
- Headache
- Nausea
- Ataxia
- Hyponatremia
- Rash
Key clinical trials
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia (PHASE4)
- Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression (PHASE4)
- Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients (PHASE1)
- Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy (PHASE3)
- Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
- Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxcarbazepine XR CI brief — competitive landscape report
- Oxcarbazepine XR updates RSS · CI watch RSS
- Supernus Pharmaceuticals, Inc. portfolio CI